Evidence map›Paper›PMID 29275364›Full record

ArticleCancer genomics & proteomics

Genetic Variations in the 3'-untranslated Regions of Genes Involved in the Cell Cycle and Apoptosis Pathways Affect Bladder Cancer Risk.

Qiang Zhang, Wenying Wang, Weidong Xu, Mulong Du`, Gaoxiang Ma, Hanting Liu, Haiyan Chu, N A Tong, Meilin Wang, Jianfeng Shao and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Qiang ZhangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China.
Wenying WangDepartment of Urology, Beijing Friendship Hospital affiliated to Capital Medical University, Beijing, P.R. China.
Weidong XuDepartment of Urology, Yizheng Hospital, Drum Tower Hospital Group of Nanjing, Yizheng, P.R. China.
Mulong Du`Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China.
Gaoxiang MaDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China.
Hanting LiuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China.
Haiyan ChuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China.
N A TongDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China.
Meilin WangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China.
Jianfeng ShaoDepartment of Urology, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, P.R. China.
Zhengdong ZhangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, P.R. China drzdzhang@gmail.com qianjing998@163.com yuanlin47@126.com.
Lin YuanDepartment of Urology, Jiangsu Province Hospital of TCM, Nanjing, P.R. China drzdzhang@gmail.com qianjing998@163.com yuanlin47@126.com.
Jing QianDepartment of General surgery, Yizheng Hospital, Drum Tower Hospital Group of Nanjing, Yizheng, P.R. China drzdzhang@gmail.com qianjing998@163.com yuanlin47@126.com.
Nanjing Medical University · CNCapital Medical University · CNIntegrated Chinese Medicine (China) · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKey genes related to cell cycle and apoptosis pathways play critical roles in bladder cancer. Single nucleotide polymorphisms (SNPs) in the 3'-untranslated regions (3'-UTR) of genes may impact microRNA (miRNA)-messenger RNA (mRNA) binding capacity and alter gene expression to contribute to the susceptibility of cancers. However, an association of genetic variations in cell cycle and apoptosis pathways with bladder cancer risk, has not been reported. MATERIALS AND

methodsWe selected SNPs in the 3'-UTR of cell cycle and apoptosis pathways genes and genotyped them with a case-control study consisting of 578 bladder cancer patients and 1,006 cancer-free subjects. Dual luciferase reporter gene assay was performed to validate the biological function of important SNPs.

resultsWe found that 5 SNPs might change the binding ability of miRNA to their target genes, among which PPP3CC rs7431 A>G located in the 3'-untranslated regions with the minimum p-value (p=5.75×10

conclusionPPP3CC rs7431 may alter miRNA binding ability of miR-212 and miR-132, and thus decrease bladder cancer risk.

Indexed as

3' Untranslated RegionsPolymorphism, Single NucleotideApoptosisCalcineurinGenes, cdcHumansMicroRNAsRiskUrinary Bladder Neoplasms3' Untranslated RegionsCalcineurinMicroRNAsMIRN132 microRNA, humanMIRN212 microRNA, humanPPP3CC protein, human3’-UTRbladder cancercell-cycle and apoptosis pathwaysmiRNASNP

Identifiers

PMID29275364
PMCPMC5822179
OpenAlexW2780480825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.